Abstract | AIM: METHODS: OA signs/symptoms were evaluated by the WOMAC scores. Mobility was studied by walking performance (treadmill), and inflammatory status was assessed by measurements of C-reactive protein (CRP). RESULTS: After three months of treatment, the global WOMAC score decreased by 58% (P<0.05), walking distance in the treadmill test was prolonged from 76 m to 332 m (P<0.05), and CRP levels decreased from 168 +/- 18 to 11.3 +/-. 4.1 mg/L in the subpopulation with high CRP. In comparison, the control group experienced only a modest improvement in these parameters (2% in the WOMAC score, from 82 m to 129 m in the treadmill test, and from 175 +/- 12.3 to 112 +/- 22.2 mg/L in the CRP plasma concentration), while the treatment costs (use of anti-inflammatory drugs, treatment and hospitalization) were reduced significantly in the treatment group. CONCLUSION: These results show that Meriva® is clinically effective in the management and treatment of osteoarthritis and suggest that the increased stability and better absorption of curcumin induced by complexation with phospholipids have clinical relevance, setting the stage for larger and more prolonged studies.
|
Authors | G Belcaro, M R Cesarone, M Dugall, L Pellegrini, A Ledda, M G Grossi, S Togni, G Appendino |
Journal | Panminerva medica
(Panminerva Med)
Vol. 52
Issue 2 Suppl 1
Pg. 55-62
(Jun 2010)
ISSN: 1827-1898 [Electronic] Italy |
PMID | 20657536
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Phosphatidylcholines
- C-Reactive Protein
- Curcumin
|
Topics |
- Adult
- C-Reactive Protein
(biosynthesis)
- Curcumin
(therapeutic use)
- Drug Synergism
- Edema
(prevention & control)
- Female
- Humans
- Inflammation
- Male
- Middle Aged
- Osteoarthritis, Knee
(drug therapy)
- Phosphatidylcholines
(therapeutic use)
- Soybeans
(metabolism)
- Treatment Outcome
- Walking
|